论文部分内容阅读
1 IntroductionThe relative contribution of bone marrow mesenchymal cells (BMSCs)-based therapy in repairing chronic myocardial infarction (MI) still calls for validation from reliable methodologies with clinical end-points~([1]). We assessed herein, by us